| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers I > Headlines for Integrated DNA Technologies, Inc. > News item |
Alnylam grants RNAi license to Integrated DNA Technologies
By Lisa Kerner
Erie, Pa., Feb. 28 - Alnylam Pharmaceuticals, Inc. has granted Integrated DNA Technologies, Inc. a non-exclusive license to provide RNA interference (RNAi) research products and services under the Kreutzer-Limmer patent family. This patent family covers small interfering RNAs and their use to mediate RNAi in mammalian cells.
RNAi is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes.
"This agreement with [Integrated DNA Technologies], one of the leading suppliers in the United States of DNA and RNA oligonucleotides for research applications, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental IP [intellectual property] in the field of RNAi," said Roland Kreutzer, managing director of Alnylam Europe AG, in a company news release.
Alnylam said it has executed a total of 20 license agreements, including 11 with research product suppliers.
The company's IP estate includes certain fundamental patents and patent applications that claim the broad structural and functional properties of synthetic RNAi products, according to the release. These patents include the Kreutzer-Limmer 1 and 2 patents, acquired through the Ribopharma merger.
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference to address significant medical needs. The company is based in Cambridge, Mass.
Integrated DNA Technologies supplies custom nucleic acids for academic research, biotechnology, clinical diagnostics and pharmaceutical development. The company is located in Coralville, Iowa.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.